Susavion has a robust pipeline of preclinical drug candidates for immunotherapy.
Multiple therapeutic indications
Susavion has developed a series of peptides that are effective at sub-nanomolar concentrations. These drugs are showing early promise in enhancing the immune defense in treatment of cancer and viral infections.
svL4 has been shown to significantly extend life of mice with ovarian cancer and significantly extends life when administered in conjunction with low doses of radiation in a glioblastoma brain tumor mouse model. svL4 reduces growth of melanoma tumors and dramatically lowers the bad, regulatory T cells within tumors. sv6D is a second generation peptide based on the parent svL4 and has significantly greater efficacy in suppression of ascites formation in a mouse model of ovarian cancer. sv6D is effective as a monotherapy and is an excellent complement to other therapies such as paclitaxel and anti-PD-1 treatments. The peptides are effective in treating melonoma, multiple myeloma, breast and renal cancer.
svH1C and sv6B completely inhibited HIV-1 replication in cultures of peripheral blood mononuclear cells in combination with non-neutralizing antibodies from HIV-positive patients.